By VETTAPHARMA reporter – Derek Roche: Eli Lilly and Company announced that Zepbound® (tirzepatide) is now available in a new multi-dose KwikPen®, marking a key expansion in how the obesity treatment is delivered in the United States.
The newly introduced pen contains four weekly doses in a single device, allowing patients to administer a full month of therapy from one pen. Previously, Zepbound was dispensed as single-dose vials. Lilly stated that the multi-dose KwikPen is available in multiple dose strengths.
According to the company, the KwikPen option is priced starting at $299 per month for eligible self-pay patients through LillyDirect. The pricing applies across approved dose strengths available through the self-pay channel.
Zepbound (tirzepatide) is approved by the U.S. Food and Drug Administration for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity. The medication activates both GIP and GLP-1 receptors to help regulate appetite and food intake.
In the same announcement, Lilly stated that Zepbound is the #1 prescribed injectable obesity-management medication in 2025, and that one out of every three new patients starting a branded obesity treatment this year was prescribed Zepbound through self-pay vials.
The company said the new multi-dose pen is intended to simplify treatment administration while maintaining the same clinical profile demonstrated in the SURMOUNT trial program. In SURMOUNT-1, adults without diabetes achieved average weight reductions of up to 22.5% (52 pounds) at the highest dose over 72 weeks.
Lilly noted that expanding Zepbound into a multi-dose pen format is designed to improve convenience and support broader patient access as demand for obesity treatments continues to rise.
